Related Experiment Video
Updated: Feb 17, 2026

OLIgo Mass Profiling OLIMP of Extracellular Polysaccharides
Published on: June 20, 2010
Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II
Louise Crowe1,2,3, Joy Yaplito-Lee4, Vicki Anderson1,2,3
1a Clinical Sciences , Murdoch Children's Research Institute, Royal Children's Hospital , Melbourne , VIC , Australia.
Abstract:
Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome is a rare X-linked condition, due to a defect in a lysosomal enzyme involved in the breakdown of glycosaminoglycans. It is a progressive condition with worsening over time; however, symptom severity and progression rates vary. Normal intellectual function has been reported in males with mild MPS II but few studies are available that provide comprehensive cognitive profiles. Enzyme replacement therapy (ERT) can stabilize physical symptoms and has become standard treatment. Whether ERT can influence cognition is currently unknown. Considering this, we conducted cognitive, fine motor, and behavioural assessments with three males (7;6-12;1 years) with mild MPS II before and after ERT. Generally, cognition, fine motor skills, and behaviour were in the normal range; however, specific deficits in attention and executive function were identified. Following ERT, some memory improvements were seen. Executive deficits remained, and processing speed declined over time.
Insights
Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome, is a rare genetic disorder. Enzyme replacement therapy (ERT) may improve memory but does not resolve attention and executive function deficits in mild cases.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome, is a rare X-linked lysosomal storage disease.
- It results from deficient glycosaminoglycan breakdown, leading to progressive physical symptoms.
- Cognitive profiles in mild MPS II, especially concerning enzyme replacement therapy (ERT), are not well-established.
Observation:
- This study assessed cognitive, fine motor, and behavioral functions in three males with mild MPS II before and after ERT.
- Participants' ages ranged from 7 years and 6 months to 12 years and 1 month.
- Assessments included standardized cognitive tests, fine motor evaluations, and behavioral observations.
Findings:
- While overall cognition, fine motor skills, and behavior were generally within the normal range, specific deficits in attention and executive functions were noted.
- Following ERT initiation, improvements in certain memory aspects were observed.
- However, executive function deficits persisted, and processing speed showed a decline over the study period.
Implications:
- ERT appears to stabilize physical symptoms in MPS II but its impact on cognition requires further investigation.
- The findings suggest that while ERT may offer some cognitive benefits, specific attention and executive function challenges may persist.
- Longitudinal studies are needed to fully understand the long-term cognitive effects of ERT in MPS II patients.
More Related Videos
08:51Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
05:32Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
Related Concept Videos
Lysosomal Hydrolases
Pedigree Analysis
Proteoglycans
Assessment of the Mouth
Mouth Inspection
The inspection begins with visually examining the mouth for symmetry, color, and size.
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...